- Home
- IPHA vs VTYX Comparison
IPHA vs VTYX Comparison
Compare IPHA & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- VTYX
- Stock Information
- Founded
- IPHA 1999
- VTYX 2018
- Country
- IPHA France
- VTYX United States
- Employees
- IPHA N/A
- VTYX N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- IPHA Health Care
- VTYX Health Care
- Exchange
- IPHA Nasdaq
- VTYX Nasdaq
- Market Cap
- IPHA 150.9M
- VTYX 154.9M
- IPO Year
- IPHA 2019
- VTYX 2021
- Fundamental
- Price
- IPHA $1.95
- VTYX $1.84
- Analyst Decision
- IPHA Strong Buy
- VTYX Buy
- Analyst Count
- IPHA 1
- VTYX 4
- Target Price
- IPHA $11.50
- VTYX $11.33
- AVG Volume (30 Days)
- IPHA 50.9K
- VTYX 1.9M
- Earning Date
- IPHA 03-20-2025
- VTYX 02-25-2025
- Dividend Yield
- IPHA N/A
- VTYX N/A
- EPS Growth
- IPHA N/A
- VTYX N/A
- EPS
- IPHA N/A
- VTYX N/A
- Revenue
- IPHA $36,202,722.00
- VTYX N/A
- Revenue This Year
- IPHA N/A
- VTYX N/A
- Revenue Next Year
- IPHA $101.65
- VTYX N/A
- P/E Ratio
- IPHA N/A
- VTYX N/A
- Revenue Growth
- IPHA N/A
- VTYX N/A
- 52 Week Low
- IPHA $1.29
- VTYX $1.67
- 52 Week High
- IPHA $3.51
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- IPHA 56.50
- VTYX 39.45
- Support Level
- IPHA $1.72
- VTYX $1.91
- Resistance Level
- IPHA $1.92
- VTYX $2.15
- Average True Range (ATR)
- IPHA 0.11
- VTYX 0.16
- MACD
- IPHA 0.02
- VTYX -0.02
- Stochastic Oscillator
- IPHA 89.74
- VTYX 4.08
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.